SCYNEXIS
SCYX • NASDAQ
SCYNEXIS is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO David Gonzalez Angulo, with a market cap of $36.3M.
CEODavid Gonzalez Angulo
Next Earnings
Upcoming earnings announcement for SCYNEXIS
Date
Thursday, May 14, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.12
Revenue Estimate
$77.0K
Earnings History
Past 12 earnings reports for SCYNEXIS
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Q4 2025 | $0.25Est: $0.19 | +31.6% | $18.6MEst: $8.1M | +130.2% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$0.17Est: -$0.20 | +15.0% | $334.0KEst: $147.7K | +126.2% | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.14Est: -$0.21 | +33.3% | $1.4MEst: $154.0K | +785.7% | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.11Est: -$0.19 | +42.1% | $257.0KEst: $137.0K | +87.6% | 10-Q |
| Mar 12, 2025 | Q4 2024 | -$0.09Est: -$0.06 | -50.0% | $977.0KEst: $7.6M | -87.2% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.06Est: -$0.07 | +14.3% | $660.0KEst: $6.2M | -89.3% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.30Est: -$0.16 | -87.5% | $736.0KEst: $2.3M | -67.6% | 10-Q |
| May 8, 2024 | Q1 2024 | $0.01Est: -$0.07 | +114.3% | $1.4MEst: $7.8M | -82.4% | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$0.39Est: -$0.20 | -95.0% | $5.8MEst: $1.4M | +323.1% | 10-K |
| Nov 13, 2023 | Q3 2023 | -$0.04Est: -$0.15 | +73.3% | $1.8MEst: $5.9M | -70.1% | — |
| Aug 14, 2023 | Q2 2023 | $2.46Est: $1.55 | +58.7% | $131.5MEst: $95.5M | +37.7% | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.71Est: -$0.28 | -153.6% | $1.1MEst: $930.0K | +21.5% | — |